Literature DB >> 16404280

Cost analysis of functional restoration surgery for extremity soft-tissue sarcoma.

Andrew A Nelson1, Frank J Frassica, Toby A Gordon, E Gene Deune.   

Abstract

BACKGROUND: Limb-sparing surgery, consisting of wide-margin tumor resection and preoperative or postoperative radiotherapy/chemotherapy, has become the surgical treatment of choice for extremity sarcomas. However, adequate tumor resection can sometimes compromise crucial limb function, necessitating functional restoration surgery. The purpose of this study was to determine the cost impact and functional outcomes of such procedures.
METHODS: Patients receiving either functional restoration surgery or soft-tissue-only reconstruction following extremity soft-tissue sarcoma excision were identified. Patients were then compared along several dimensions: overall length of stay and its subdivisions, surgical time, and total charges and its subdivisions. Patients' functional outcomes were assessed with the Toronto Extremity Salvage Score.
RESULTS: Sixty-seven patients who underwent 69 limb-sparing procedures were identified. Fifteen of these procedures (eight upper extremity, seven lower extremity) required functional restoration surgery; 54 of these procedures (13 upper extremity, 41 lower extremity) required only soft-tissue coverage. In the upper extremity, there was a statistically significant increase in overall length of stay (2.8 days) and its subdivisions, surgical time (3.7 hours), and total charges (12,484 dollars) and its subdivisions associated with performing functional restoration surgery. In lower extremity cases, statistically significant increases were determined in only the total charges (9190 dollars) and medical supply charges (13,204 dollars) following functional restoration. Patients who underwent functional restoration surgery had better postoperative function (mean Toronto Extremity Salvage Score, 82 versus 80), but this difference was not statistically significant.
CONCLUSION: Although functional restoration surgery is more costly than soft-tissue reconstruction alone, the authors believe that the associated better functional outcome justifies its performance.

Entities:  

Mesh:

Year:  2006        PMID: 16404280     DOI: 10.1097/01.prs.0000187140.83705.cf

Source DB:  PubMed          Journal:  Plast Reconstr Surg        ISSN: 0032-1052            Impact factor:   4.730


  5 in total

1.  The cost of laparoscopic myotomy versus pneumatic dilatation for esophageal achalasia.

Authors:  Paul J Karanicolas; Shona E Smith; Richard I Inculet; Richard A Malthaner; Richard P Reynolds; Ron Goeree; Amiram Gafni
Journal:  Surg Endosc       Date:  2007-05-04       Impact factor: 4.584

2.  Concomitant upper extremity soft tissue sarcoma limb-sparing resection and functional reconstruction: assessment of outcomes and costs of surgery.

Authors:  Gerhard S Mundinger; Roni B Prucz; Frank J Frassica; E Gene Deune
Journal:  Hand (N Y)       Date:  2014-06

3.  Clinical implications of determination of safe surgical margins by using a combination of CT and 18FDG-positron emission tomography in soft tissue sarcoma.

Authors:  Masahiro Yokouchi; Mikio Terahara; Satoshi Nagano; Yoshiya Arishima; Michihisa Zemmyo; Takako Yoshioka; Akihide Tanimoto; Setsuro Komiya
Journal:  BMC Musculoskelet Disord       Date:  2011-07-21       Impact factor: 2.362

4.  Staged reconstruction brachytherapy has lower overall cost in recurrent soft-tissue sarcoma.

Authors:  Arash O Naghavi; Ricardo J Gonzalez; Jacob G Scott; Youngchul Kim; Yazan A Abuodeh; Tobin J Strom; Michelle Echevarria; John E Mullinax; Kamran A Ahmed; Louis B Harrison; Daniel C Fernandez
Journal:  J Contemp Brachytherapy       Date:  2017-01-31

5.  Functional Outcome Measurement in Patients with Lower-Extremity Soft Tissue Sarcoma: A Systematic Literature Review.

Authors:  Gilber Kask; Ian Barner-Rasmussen; Jussi Petteri Repo; Magnus Kjäldman; Kaarel Kilk; Carl Blomqvist; Erkki Juhani Tukiainen
Journal:  Ann Surg Oncol       Date:  2019-08-12       Impact factor: 5.344

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.